AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05076695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg loading dose IV, then 6 mg/kg IV, every 3 weeks for a total of 6 administrations.
Study NCT05076695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: Pyrotinib 400mg, PO daily, continuously
Study NCT05076695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Fulvestrant will be administered according to local prescription guidelines and will be given intramuscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose.
Study NCT05403255 — intervention group
Intervention type: OTHER
Intervention: evaluation of the quality of life with questionnaires
Description: Questionnaire data will be collected among patients and their parents during follow-up consultations.~Children's quality of life will be evaluated using the Kidscreen-10 questionnaire (for children and parents) and PedsQL multidimensional fatigue scale. Psychosocial indicators (standard of living, schooling, recreation activities, social and family relationships, perceived health status and physical appearance) will be gathered using a questionnaire based on the HBSC (Health Behaviour in School-Aged Children) questionnaire (INPES 2010), and compared with data from the general population of elementary-, middle-and high-school children in France.
Study NCT05390801 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey developed by ophthalmologists from the Ophthalmology Department of the Necker-Enfants Malades Hospital, fill out only once by patients with congenital aniridia in order to identify eye and systemic manifestations in congenital aniridia and to determine the patients' knowledge of their own disease.
Study NCT06017479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin 3000 MG
Description: Fosfomycin 3 g single dosage 1 hour before the urodynamic examination
Study NCT06017479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500 mg single dosage 1 hour before the urodynamic examination
Study NCT06433024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PPG Diagnostic
Description: The study investigates venous competence through three distinct exercises using photoplethysmography (PPG) technology to record blood flow in the leg veins of 20 subjects, split into two groups: those with chronic venous disease (CVD) and those without. The null hypothesis is that there will be no significant difference in venous filling times (VFT) and PPG trace variations between subjects with CVD and those without under different physical conditions. The alternative hypothesis suggests that individuals with CVD will show distinct PPG patterns, particularly shorter VFT and varied pressure changes, indicative of venous reflux or obstruction. This hypothesis is chosen based on prior evidence suggesting observable differences in venous function between affected and non-affected individuals.
Study NCT05777577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic therapy
Description: probiotic including bifidobacterium
Study NCT06149741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Defunctioning left-sided loop colostomy
Description: Descending or left transverse double-barrelled loop colostomy in left iliac fossa after complete splenic flexure mobilisation, mesorectal excision, and anastomosis.
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT04177004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT04747236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Azacytidine, 300 mg po daily on Days 1-14
Study NCT05433792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myolens CN (Central-Near) soft contact lens
Description: Personal fitting of the Myolens-CN/CF.
Study NCT05433792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MiSight® soft contact lens
Description: Control arm device, FDA approved (P180035), and CE marked soft lenses for the management of Myopia in children aged 8-12.
Study NCT05144360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenas
Description: ATENAS 1 coated tablet, once a day EMPAGLIFLOZIN PLACEBO Empagliflozin placebo 1 coated tablet, once a day TELMISARTAN + AMLODIPINE PLACEBO Telmisartan + amlodipine 1 coated tablet, once a day
Study NCT05144360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenas placebo
Description: Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day. Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day ATENAS PLACEBO Atenas placebo 1 coated tablet, once a day
Study NCT05612789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program (Cohort A Prehab)
Description: Pre-frail and frail potential HCT recipients 60 years and older will participate in a supervised exercise program from the time of enrollment up until HCT admission. Exercise compliance will be measured in part through physical activity trackers.from time of discharge from HCT until day +100 post-HCT. All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
Study NCT05612789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program (Cohort B Rehab)
Description: All HCT recipients 60 years and older will participate in a supervised exercise program from the time of discharge from HCT admission until day +100 post-HCT. Exercise compliance will be measured in part through physical activity trackers.
Study NCT04908878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral nerve (PECS) block -transversus thoracic plane (TTP) block
Description: Patients will receive unilateral US-guided PECS II block and TTP block on the side of the operation after induction of general anesthesia.
Study NCT04908878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane (SAP) block
Description: Patients will receive US-guided SAP block after induction of general anesthesia.
Study NCT05132920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 3 x 8 mg dexamethasone daily for days 1-7 and 1 x 8 mg dexamethasone daily for days 8-21
Study NCT05132920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
Study NCT04925362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological specimens
Description: Biological specimens are collected to better characterize patients of different severity and improve our understanding of clinical and histological heterogeneity at diagnosis :~* added for the research : blood, urine, stools~* collected for the research : liver tissue sample, if a liver biopsy is indicated for clinical reasons (standard of care)
Study NCT04925362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional visit
Description: Visits if possible during standard care, otherwise added by the research (If necessary the annual visit will be added by research for the collection of biological samples)
Study NCT05385731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Walking (NWG)
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study NCT05385731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NWG)
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study NCT05385731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Walking (FWG)
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study NCT05385731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Walking (FWG)
Description: 24 sessions will be held twice a week, with each session taking an average of 60 minutes.
Study NCT05385731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HEG)
Description: The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months.
Study NCT05385731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education (HEG)
Description: The control group will receive orientation and carry out the Health Education program and will have a duration of 3 months.
Study NCT06177327 — intervention group
Intervention type: OTHER
Intervention: Screening for hepato-bilio-pancreatic abnormalities in Fibrous dysplasia of bone /McCune Albright syndrome , description and characterization of the lesions.
Description: Data collection from hepato-bilio-pancreatic Magnetic Resonance Imaging realized during the follow up of patients with Fibrous dysplasia of bone /McCune Albright syndrome
Study NCT05175898 — intervention group
Intervention type: DEVICE
Intervention: VA-ECMO
Description: Treatment with veno-arterial extracorporeal membrane oxygenation
Study NCT05175898 — intervention group
Intervention type: DEVICE
Intervention: ECMELLA
Description: Treatment with veno-arterial extracorporeal membrane oxygenation plus Impella® micro-axial pump.
Study NCT05461313 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Constrained Liner
Description: Subjects in this arm will receive a constrained liner with one of the following implants: Freedom Constrained Acetabular Liner (Zimmer Biomet), G7 Freedom Constrained Acetabular Liner (Zimmer Biomet) or Lubinus Acetabular Cup with a safety ring (LINK)
Study NCT05461313 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dual Mobility
Description: Subjects in this arm will receive a dual mobility cup with the following implant: Avantage Dual Mobility Cup (Zimmer Biomet)
Study NCT05051982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sedline EEG in View
Description: EEG monitor (Sedline) will be in full view of the Anesthesiologist during surgery.
Study NCT05939076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Arctic Front™ Cryoballoon Advance, Medtronic, for pulmonary vein isolation
Study NCT05939076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™
Description: Antiarrhythmic drugs
Study NCT04747236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
Study NCT04747236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: Romidepsin, 14 mg/m2 as an intravenous infusion over 4 hours on Days 8, 15, and 22 of a 35-day cycle
Study NCT04747236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belinostat
Description: Belinostat, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1-5 every 21 days.
Study NCT04747236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pralatrexate
Description: Pralatrexate, 30 mg/m2 as an intravenous infusion over a 3-5 minute push once weekly for 6 weeks of a 7 week treatment cycle.
Study NCT04747236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, 1000 mg/m2 as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of a 28 day cycle.
Study NCT05570656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XSENS-Awinda
Description: The participant wears inertial sensors X-Sens that measure the kinematic data and the amplitude of joint movements during different movements (flexion and extension of the spine, walking, picking up an object on the ground, tying their shoelaces, getting up from a chair... ) Each movement will be repeated 3 times.~Participants will also have self-questionnaires to complete (BASDAI and BASFI).~The exams are carried out on one day.
Study NCT04706312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stem cells
Description: hAMSCs injection via venous in the dorsum of hand
Study NCT03978611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study NCT03978611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT05130385 — intervention group
Intervention type: DEVICE
Intervention: High-resolution optical coherence tomography (High-Res-OCT)
Description: Imaging with high-resolution optical coherence tomography
Study NCT06425250 — intervention group
Intervention type: OTHER
Intervention: Management, progression and risk factors for failure of BJI caused by Campylobacter spp.
Description: Description of demographic data (sex, age), comorbidities (ASA and Charlson scores), orthopedic and septic history, and surgical and medical management (antibiotic therapy)
Study NCT06425250 — intervention group
Intervention type: OTHER
Intervention: Description of the evolution and risk factors for failure of osteoarticular infections caused by Campylobacter spp.
Description: Failure of treatment: defined according to a composite criterion bringing together~* persistence of the infection under treatment, and/or~* recurrence of the infection after stopping antibiotic therapy, and/or~* need for surgical revision for septic reasons more than 5 days after initial treatment, and/or~* superinfection, and/or~* definitive explantation of the material, and/or~* decision for suppressive antibiotic therapy, and/or~* amputation, and/or~* death linked to infection
Study NCT06296992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week TEAM peer mentor program
Description: A 12-week peer-led behavioural intervention that supports increased physical activity. It will consist of 3 weekly contacts between participants and peer mentors that will be a mix of in-person, virtual, and texting. The intervention components and communication between adolescents and peer mentors with T1D will be guided by SDT, and designed to overcome the key psychosocial barriers to PA. The peer mentors that complete the training will deliver a 12-week intervention to increase behavioural skills that foster autonomy for goal setting and overcoming barriers to PA.
Study NCT06321224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises will be performed 3 days a week during 2 menstrual periods.
Study NCT06321224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention will be made to the control group and they will be asked to continue their routine lives.
Study NCT05224557 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05508607 — intervention group
Intervention type: OTHER
Intervention: CDI-risk Classification Tool
Description: This tool will focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
Study NCT05200546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: molecular assays to screen for eXDR
Description: VRE detection will be performed using VIASURE Vancomycin resistance Real Time PCR Detection Kit.~BD MAX Check-Points CPO will be used to detect carbapenemase-producing organisms.
Study NCT05508841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS and Cognitive Training
Description: Participants will receive mild stimulation or no stimulation along with cognitive training
Study NCT05508841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS and Cognitive Training
Description: Participants will receive mild stimulation or no stimulation along with cognitive training
Study NCT05508841 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS and Cognitive Training
Description: Participants will receive mild stimulation or no stimulation along with cognitive training
Study NCT05755776 — intervention group
Intervention type: DRUG
Intervention: TMF
Description: switch ETV to TMF
Study NCT05323279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence assistance system
Description: The artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed and feedback the overspeed percentage.
Study NCT05130385 — intervention group
Intervention type: DEVICE
Intervention: Standard spectral domain OCT (SD-OCT)
Description: Imaging with standard spectral domain OCT
Study NCT05379764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embodiment
Description: Embodiment of a real human in a virtual human (avatar) means that the real human feels incarnated in the avatar. This happens when the real human sees the VRscenario from first person perspective, that the real human can make the avatar move (=agency over the avatar), multi-sensorial integration (=there is a link between the brain of the real human and the avatar. Example, when the avatar sits on a chair, the real human will too and he feels that he is sitting on a chair. Or when the avatar is moving the real human is doing the same movement (and of course the brain of the real human is aware of this movement)) and co-location (= avatar and real human have the sane posture).
Study NCT05379764 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Observation
Description: The person is looking at the VR scenario as if s/he was looking at a TV
Study NCT06391970 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cognitive screening
Description: The cognitive abilities of participants will be assessed using two different interventions: the first utilizing the new digital device, and the second employing the gold standard method.
Study NCT04925219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely supervised exercise programme
Description: Electronic walking log Fortnightly video/telephone calls with physiotherapist
Study NCT04925219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed exercise
Description: Electronic walking log and instructions to exercise 4 times per week.
Study NCT04535102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin is an ADC designed for the targeted delivery of MMAE(mono-methyl auristatin E), a potent microtubule inhibitor to lymphoma cells expressing CD79b. MMAE has a mechanism of action that is similar to that of vincristine.
Study NCT05476380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Camrelizumab:200 mg, IV., d1, q3w; Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w; Cisplatin:75 mg/m2, iv., d1,q3w
Study NCT05732493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab 300mg, d1, q3w
Study NCT05732493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short-term radiotherapy
Description: radiation: 25Gy/5Fx
Study NCT05732493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2 d1 q3w
Study NCT05732493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 d1 q3w
Study NCT05732493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 d1-14 q3w
Study NCT05732493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 d1-14 q3w
Study NCT05876767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR444336
Description: Single or repeated dose subcutaneous injection
Study NCT06393413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiedu Yizhi Formula
Description: Observation after 24 weeks of drug treatment
Study NCT06393413 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Donepezil Hydrochloride Tablets
Description: Donepezil Hydrochloride Tablets
Study NCT06134115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipocet® (food supplement)
Description: 1 sachet, 10 ml corresponding to 1500 mg of Cetylated fatty acids
Study NCT06052605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Aging in People with Epilepsy Program
Description: This a 12-week group educational program providing education on healthy aging, chronic disease management, dementia, and modifiable lifestyle dementia risk factors.
Study NCT06134115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lipocet Placebo
Description: Lipocet Placebo matching to Lipocet
Study NCT05034042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: oral
Study NCT05034042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT05876767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or repeated dose subcutaneous injection
Study NCT03792295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetominophen, ibuprofen, oxycodone
Description: Multimodal pain treatment group
Study NCT03792295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Classic opiod pain treatment group
Study NCT06201429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Tissue Resuscitation (MTR™)
Description: Mechanical Tissue Resuscitation (MTR™) to externally drain excess fluid volume from the site of surgery in patients who have undergone a surgical procedure (craniotomy/craniectomy) for which a portion of the skull has been removed resulting in exposure of the dura/brain and require drainage of fluid.